Compare Snowflake Inc (SNOW) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snowflake Inc vs Sanofi SA — how do they compare? Snowflake Inc trades at $331.64 (market cap $118.36B), while Sanofi SA trades at $43.14 (market cap $104.06B). The key difference: Snowflake Inc and Sanofi SA are close in size by market cap, and Sanofi SA pays a 5.61% dividend while Snowflake Inc pays none. Which is the better fit depends on your goals.
| SNOW | SNY | |
|---|---|---|
Market Cap | $118.36B | $104.06B |
Sector | Technology | Health |
52-Week High | $356.47 | $52.34 |
52-Week Low | $121.11 | $41.33 |
Enterprise Value | $118.78B | $124.09B |
Dividend Yield | — | 5.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Snowflake (SNOW) trades at $335.50, down 0.5% on the day, but maintains strong technical momentum with bullish moving averages and support at $331. The company demonstrates accelerating revenue growth, with Q2 2026 EPS beating expectations at $0.62 versus $0.45, and product revenue up 37% year-over-year. Recent news highlights AI-driven customer expansion and improved guidance, with the stock gaining 67% year-to-date in 2026.
Snowflake presents a growth-oriented investment case with robust AI adoption and enterprise expansion driving revenue acceleration. However, negative profitability metrics and elevated valuation multiples (P/S 21.25, P/B 55.06) pose significant risks. Analyst consensus remains strongly bullish with a $430 price target, but investors must weigh growth potential against persistent losses and competitive pressures in cloud analytics.
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
